mp.weixin.qq.com·· 6 hours agoPickScore74
EQT to Acquire QIAGEN in All-Cash Deal Valued at About 10.8 Billion Euros
In brief
Swedish private equity firm EQT announced a voluntary public all-cash offer for Dutch molecular diagnostics company QIAGEN through its indirectly controlled Crown NL Bidco B.V., at 46.50 euros per share, for an enterprise value of about 10.8 billion euros (including net debt of about 1.1 billion US dollars and equity value of about 9.6 billion euros). EQT manages 354 billion euros in assets, has invested more than 30 billion euros in healthcare, and its past portfolio includes Galderma, Parexel and Aldevron.
Why it matters
The brief gives per-share price, enterprise value and net debt figures, letting readers compare them with QIAGEN's market value and EQT's healthcare investments.
Source: mp.weixin.qq.com · mp.weixin.qq.com